This page is for discussion of Arch Therapeutics (ARTH).
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
$ARTH long
https://ir.archtherapeutics.com/press-releases/detail/531/arch-therapeutics-announces-2-5-million-registered-direct
Question from a concerned investor.
Iโve invested in ARTH for three years now and hold a fair amount of shares. Should I be moving on? Is there any hope left that this company is actually going to produce stock revenues? Please!
ARTH is about to get the CE Mark for Europe. They’ve put AC5 in the hands of Key Opinion Leaders to get some case studies and start a buzz. They’ll file the IND for internal use in December or January. They are talking to multiple potential distribution partners around the world.
JohnM is on top of it. We are all waiting for the CE approval, there has been reasons given for the delay, but no facts. The only thing that can be done is to call Terry Norchi for and update. Perhaps Cleveland will stop b y if he is up to taking more abuse.
Alas, frenigon, we’re all concerned investors.
I’m hanging on to my holdings because I seem to suffer from the usual malady that as soon as I sell something, the share price goes up, and that would irritate me in the extreme after my years of holding $ARTH (since 4/30/2015).
And no., fellow $ARTH holders, I do not wish to sacrifice my shares in order to benefit the share price for the group. Sorry.
May we all yet bask on that island in the sun when we go on our victory vacation together.
Penny
We have about 37 days of fall left. Is TN going to be true to his word or not? If past performance is any indication, not. However, for the 510K approval, we did get it about when TN said we would last December. It was at that time I discussed the fact that the US Gov. closes down pretty much for the holidays and as a result they would be rushing to get all signatures needed done before the 15th. The 180 days for a 510K put it in the last week of Dec. And sure enough, the approval came before the 15th.
Now, EU government organizations are no different then the US Governments. They pretty much close down from the 15th onwards. 37 days till winter is Dec 22, drop that back to the 15th and we have 30 days left for a decision this year or it goes to next year.
Tick Tock Tick Tock
Come on TN, make us proud.
Come on British Standards Institute, make us…well, not proud of an organization that has missed their May 28 deadline by five months, seventeen days and counting…but at least think there’s a shred of competence left.
$ARTH
CEO loves his job, travel, salary. May be after another 5 years ARTH have many more FDA approvals for different indications and no product in the market and telling investors that they are chasing approval for next big revenue stream. My ARTH dreams are dashed long ago and out.
Hope I am wrong… good luck to all ARTHs
just a thought, if I had put the same money invested in ARTH into AAPL, AMZN, MSFT, GOOG itโs worth more than double now. Hmmm…
Ah, but you didn’t . . .
$ARTH atlas long
https://ir.archtherapeutics.com/all-sec-filings/content/0001104659-19-065500/tm1919813d1_10k.htm
“We completed the biocompatibility studies required to initiate our first human trial of AC5 in Western Europe”
“Our commercialization plan for at least some of our product candidates could entail entering into one or more collaboration agreements or strategic partnerships.”
“The Company was recently notified by its Notified Body that its review team has completed its review of the Archโs technical documentation and that it has recommended to its decision making panel that CE Marking be granted. This process is expected to be completed in early 2020.”
Great news..! They need to knuckle down and start getting busy. They shouldn’t even wait for CE confirmation and a deal – they should be working on getting the internal trials up and running. We don’t know what an external AC5 deal could bring – maybe not much. The money is in internal. So let’s get going..!
Except the rest of the 10-k wasnโt as positive. Delays in getting KOLs trials of AC5. Dilution in 2020 (while TN gives himself and others big raises). Internal development probably not making much headway until later 2020, early 2022.
No transparency or communication. OW and frustrated.
It all comes down to money. And funding. Most of the report is boiler-plate. Essentially they reserve the right to do this or that. Including raising money when they want. We know that. Let’s hope an external deal can be cut to minimize that. If not. Well they need to dilute. More. Quit putting it off. They have products that if approved will be cash-cows. Move on it now.
when do the cows come home to roost for followers of this nonsense. JMbanks , among many others have realized this is going no-where. elvis left the building years ago when avatar came on board. with his background it was obviously it was going to develop into a cash cow only for ceos etc. norchi is loving it as much as avatar. living high off the hog on dumb money,,,,,,, tax loss time is upon you, perhaps its time. if it was possible, it would hv been bought out or to market.
I don’t really buy that. At all. The original CE application got screwed up. It shouldn’t have. But human error got it submitted as a drug as opposed to a device. After that… They were on a roll. Their website had goals listed – they were knocking them down. Then – the FDA comes back on em at the 23rd hour for more info. And it is debatable whether they should have. And then all hell broke loose. Everything got massively delayed. External products started entering the market place. etc.
Everyone – including Dr. Kiss – was saying the external was just a sideline. and they have been hung up on it. The other stuff is still there. They just need to get on it.
dr kiss left this lock stock n barrel before he left gumshoe……
Agreed. The only reason I mentioned him was because he was the guy who brought it here. It is a start up company. High risk. High reward. We will see how it plays out.
It occurred to me today with all the noise on the news about the impeachment inquiry. What if the holdup with the CE approval was political in nature our POTUS is not all that popular in the world. That should add a little more life to the discussion pardon me if I don’t answer.
Well, in doing some digging into the 10-k, I see some positive information. First, the Notify Body has recommended approval of the CE Mark as noted above in finventurer’s post. Which would mean that the CE Mark will be approved. The down side is that rather then getting the approval this year, it looks to be early 2020, for the same reason that TN stated earlier this year, there is a backlog of CE Mark submissions. Now this does not mean that approval in 2019 is off the table. TN is just covering his backside.
Another gem from the 10-k, they are adding a European supplier and manufacturing process. So they will have one in the USA and Europe. That to me is a good thing. Why add a supplier if they did not think they were going to be able to sell a lot of product. Apparently TN intends to use the product produced in Europe to sell in the USA and as a result this will take approval from the FDA which they expect early 2020.
Another thing to remember, this 10-K was for the fiscal year ending Sept, 2019. We do not know what the rest of this year will hold for Arth. Their Oct 7 press release stated “Arch awaits acknowledgement that the notified body has completed its review process, and the next update is expected to coincide with a definitive and material announcement.” So, based on the 10-k, the review process has been completed with a recommendation to approve. Now TN, it is time for your definitive and material announcement please.
@rlamore – Here’s the SA link
https://seekingalpha.com/article/4308381-arch-therapeutics-receives-recommendation-ce-mark-granted
Be still my heart! $ARTH is at 0.288 on a steady rise. Can something be happening???
@drbonz – Have you survived the past couple of months?
Happy Thanksgiving for yesterday to all the biotech-following (and other) Gummies.
Cheers,
Penny
Does anybody know where the CE certification for ARTH is being done?
Planning on storming the building and demanding action? ๐
Merry Christmas
Letโs see… no commercialization s after 1 year of approval.
No CE Mark approval yet.
No internal trials announced yet.
Much dilution for running of business.
What a waste of a year except for Terry and his 1 million more options!
Happy Holidays!
drbonz, “storming the building” probably would just cause a legal problem but storming the next AGM might get something done. `ARTH management should have been able to give us a heads up on what is going on. The lack of information on a process that is now 3-4 times past due makes the whole situation suspect. I was part of a group that held stock in a company listed on the ASX and was suspended. We were able to through the ASX file complaints and force an EGM (emergency AGM). At the EGM we removed the board of directors and management. We now have a BOD that at least keeps the stock holders informed at least as much as the ASX will allow. Could that here probably not as you need a certain percentage of the stock holders to be recognized. It doesn’t get done without a little effort.
I the question that I asked that started these comments because I seem to remember that the company doing the certification was in the UK. It seems to me that a certification that affects multiple countries would be effected by BREXT if the company doing the cert was in the country with drawing from the Union. The searches I did said otherwise but I think that maybe BULL.
@griffin
When is the next Arch AGM ? Where? I like your idea of storming the AGM. We need proxies!
Wasn’t there somewhere, in the glorious past, a spreadsheet showing the $ARTH holdings of the Gummies (as self-reported)? The total was a considerable number I believe. Of course not the same numbers now. Does the spreadsheet still exist?
Happy New Year Penny. I’m not sure who compiled the list. It could have been Cleveland or Alan Harris,or? Travis or Lynn should be able to advise as to whether either of these 2 are still part of the SG flock.
Regards,
Frank
If we were going to do something constructive we would have to know what percentage of share holders to be recognized, it might not be many, AGMs’ draw a small crowd. The Skype group I joined had some knowledgeable people in it, we still haven’t been relisted ๐
There were 2-3 spreadsheets I don’t remember a tally of ARTH shares. I think I have a copy of most of those available on google.docs. IIRC it was Glen Newberry aka “opposable thumbs” that did the sheets. The last time I checked the spread sheet was gone.
$ARTH long
I don’t really like talking about #’s, but FWIW, I have 100k in ARTH.
Cheers all – Todd
The European equivalent of the FDA is the EMA. It relocated from London to Amsterdam due to Brexit.https://www.ema.europa.eu/en/news/ema-now-operating-amsterdam . It also recently changed the approval process for medical devices. So two factors that have had an impact on the approval timeline!
The European equivalent of the FDA is the EMA. It relocated from London to Amsterdam due to Brexit.https://www.ema.europa.eu/en/news/ema-now-operating-amsterdam . It also recently changed the approval process for medical devices. So two factors that have had an impact on the approval timeline!
Happy Holidays!
Thank you, Thank you, mtpoulsen nice Xmas present I’ll follow up on the link a bit more. The moves have affect the employees, not only that, but they are building a new facility. They started this in the summer of 2018. Sincerely Larry
A ‘General Inquiry’ has been submitted but there will not be an answer till next month.
Mid year 2019 report link from EMA a lot going on 88 pages worth;
https://www.ema.europa.eu/en/documents/report/european-medicines-agency-mid-year-report-2019-executive-director_en.pdf
more when I find it.
Link to the medical device classification and process https://www.ema.europa.eu/en/human-regulatory/overview/medical-devices
AC5 probably falls under โmedical devices are made of substances that are systemically absorbedโ Applications for a CE mark of a medical device can be filed in any if the EU member states. Each member state has a number of approved โnotified bodiesโ – like this one for Ireland https://ec.europa.eu/growth/tools-databases/nando/index.cfm?fuseaction=country.notifiedbody&cou_id=372 The notified body does the ground work for approval and then consults with the EMA. If the EMA agrees with the recommendation the CE mark is granted and valid throughout the EU. So to understand which specific certification agency deals with the AC5 application we need to know which country it was filed in.
Thanks for the follow up. The link to the medical devices’ info doesn’t appear to have any problems as the new regulations went into force May 2017 which IIRC is prior to the submission of AC5. Any other pending regulations seem to pertain to co-packaged devices, (drug & device), and AC5 is not. The country that the application was filed in could be a problem unless there is a work around for the USA. I think that Arch has sales agreement with distributor in Europe and that may have been done, since no sales yet, to facilitate the CE application, but in who’s name and what country. I’ll send Arch IR an email as that info they might give out a more freely than CE.
$ARTH long. Corporate update.
https://ir.archtherapeutics.com/press-releases/detail/532/arch-therapeutics-to-provide-corporate-update-at-biotech
$ARCH – Arch Therapeutics Inc, Inst Holders, 4Q 2019 (ARTH)
” Arch Therapeutics Inc, Inst Holders, 4Q 2019 (ARTH) 3:24 AM ET 1/19/20 | Dow Jones
The following table shows the largest shareholders in ARCH THERAPEUTICS INC COM (ARTH) for the quarter ended December 31, 2019, listed by holding size. The list represents up to 50 of the largest holders in the company.
Note: Unless otherwise mentioned the reporting date is 12/31/2019
Institution Shares Shares % Last
Held Changed Held Report
The Bryn Mawr Trust Co. 15,000 0 0.008 09/30
PanAgora Asset Management Inc 0 (26,115) 0.000 09/30
Cribstone Capital Management L 0 (25,288) 0.000 12/31
13F data provided by: Factset Research Systems Inc.;
Please send questions to ownership@factset.com.
Copyright, Factset Research Systems, 2020. All Rights Reserved.
> Dow Jones Newswires
January 19, 2020 03:24 ET (08:24 GMT)
ARCH long
@griffin Thanks for institutional holdings link. (I’m a bit late responding.)
Jeez, I hold more shares than that sole institutional organization Bryn Mawr Trust does (as I am sure most of us out here in Gummyland do)!
And Cribstone & PanAgora sold theirs. Pikers! (using the Australian meaning)
Penny
Pikers or, “a lot smarter than us”?
Well now, drbonz, finally, a smile out of all this! Thank you.
When ever I run into something I can cut&paste for the Gummies I try to help. I’m having computer problems and email, just got your reply this morn.
I’m not holding my breath for CE certification. Considering that the certifyer (EAM?) planned their move ahead of time. It would have nice if TN given a heads up.
Today is about the half-way point of 1st Qtr. 2020. In announcements late last year, TN told us that a committee had recommended CE approval for AC5 to the main European body. TN also stated that he expects to have this approval and several distribution deals completed in the 1st Qtr. 2020.
We have 6 weeks left in the 1st Qtr, 2020. Good news is announced on Mon/Tues of the week and bad news on Fridays. So, which of the next 6 Mon/Tues will it be? Or is TN just once again blowing smoke up our you-know-whatโs?
I’m going with Option B.
The past many years of broken promises would definitely suggest option would be the one to bet on, but I would sure like to be wrong.
The trend is *cough* your friend. *cough*
I’m also expecting Option B.
$arth
https://ir.archtherapeutics.com/news/detail/533
Are we ever going to hear back about the CE mark? At this point does it even matter?
I sent an email to the CFO to the address given on the Arch Therapeutics website and also to customer relations. I received no reply. I wrote again, NADA. Sad.
Thanks for trying, @drbonz . (And to think that you have more medical credentials even than most of us out here in the Gummiverse.)
Are you up to trying again? 3rd time’s the charm???
And when’s/where’s that annual meeting again???
Link for AMENDED AND RESTATED BYLAWS OF
ARCH THERAPEUTICS, INC.
https://www.sec.gov/Archives/edgar/data/1537561/000114420413036221/v348381_ex3-1.htm
And still I ask, when’s that annual meeting?
The annual meeting ought to be in the months closely following the end of the fiscal year. There are stipulations about the annual meeting in the Articles, but FAR too many to copy & paste here, sorry .
“Section 11.3 Fiscal Year.
The fiscal year of the Corporation shall begin the first day of October of each year or upon such other day as may be designated by the Board of Directors.”
Here is a copy of what I sent them. I wanted to emphasize the medical implications more so than me simply wanting to make money.
I have been a shareholder in ARTH for nearly 5 years now and obviously my interest is driven by this fact since weโd all like to make money. However, perhaps more importantly is the fact that I am also an orthopedic surgeon. I have read everything there is to know about AC5 and how it works and I believe it can truly be revolutionary in my field and in all surgical fields.
Late 2019 Dr. Norchi told us that he expected to have CE approval and several distribution deals completed in the first quarter of 2020. We are now in the middle of the first quarter of 2020 and I was wondering if there was anything you could pass along as far as a progress report or any information on the direction ARTH is going presently and going forward. Are any new studies being completed or planned? What is the current financial situation of the company?
As stated, I would love to see ARTH shares go up as it would benefit me financially, but even more so, I would love to see AC5 in the hands of every surgeon in the country and in Europe. Using it could truly change the way we perform surgery and could benefit millions of patients worldwide.
I thank you for your time.
Sent this twice inside of two months and never heard back.
Thank you for at least attempting to get feedback.
Itโs truly remarkable the lack of transparency the mgmt team have given the shareholders. I too, have been in ARTH for years at this point. While I lack a medical background, I still believe the value here is the science.
At this point, the best I can hope for is that ARTH gets CE approval and I cAn sells on the news. Would love to hear what those who praised the stock in the past and had communication with Norchi and team think now.
Good letter, disappointing that IR has not responded.
Also, FWIW, I did some digging into the other companies mgmt has been involved in. I found the yearly increases in bonuses and salary by Norchi and others irritating given the lack of progress. I donโt know much about Left or his credentials but came across this report thatโs I found alarming:
https://citronresearch.com/wp-content/uploads/2019/04/Citron-presents-the-Red-Flags-Why-the-SEC-should-investigate-Village-Farms.pdf
And of course, just to keep us on our toes, we read the find print at the end.
The very last sentence of the actual Citron report:
“We expect that when investors look past the paid stock promotions… the stock will quickly trade back to $1 if it doesnโt get halted before that.”
Here’s one para in the usual disclaimer as required by law:
“You should assume that, as of the publication date of a Citron report, Citron Related Persons (possibly along with or through its members, partners, affiliates, employees, and/or consultants), Citron Related Persons clients and/or investors and/or their clients and/or investors have a position (long or short) in one or more of the securities of a Covered Issuer (and/or options, swaps, and other derivatives related to one or more of these securities), and therefore may realize significant gains in the event that the prices of a Covered Issuerโs securities decline or appreciate. Citron Research, Citron Capital and/or the Citron Related Persons may continue to transact in Covered Issuersโ securities for an indefinite period after an initial report on a Covered Issuer, and such position(s) may be long, short, or neutral at any time hereafter regardless of their initial position(s) and views as stated in the Citron research. Neither Citron Research nor Citron Capital will update any report or information to reflect changes in positions that may be held by a Citron Related Person.”
What’s to think???
Maybe I’ll just go out and buy a cartload of toilet paper to hoard (not really, I’m not one to panic.)
Keep the faith, peeps.
Penny
I re-read the report this morning before posting and caught that as well. Much to my surprise, I started revisting Emerald Therapeutics after posting and found this gem:
https://www.nasdaq.com/articles/village-farms-resolves-dispute-with-emerald-health-takes-control-of-joint-venture-2020-03
I don’t know if I’d classify it as panicking, but I’ve certainly become more negative in regards to $arth as time goes on. The more I dig into the Dhillons’ business ventures, the more I regret. Across the board, the companies they are involved in as of late seem to flounder.
I hope I’m wrong, I really do.
@JMB44 Another relevant article; thanks for posting the link. The part about the Dhillons’ involvement in various companies was quite interesting. Do we shareholders have enough collective clout to vote Avtar Dhillon off the board?
I hope, but probably not. I always found it questionable that wherever he goes, his nephew Punit follows.
In any case, some possible good news?:
https://ir.archtherapeutics.com/news/detail/534
To have KOLs co-present the product is a good sign. Also looks as though theyre Moreno aggressively eyeing the internal market.
Thoughts?
*more… autocorrect
Well written @drbonz. I’m also disappointed that you haven’t had a response from anyone at Arch Th.
The suffragette in me wants to march in front of their offices carrying a banner demanding some transparency and communication.
“I’m a shareholder not a mushroom. Show me some light and stop feeding me BS.”
Thank -you Dr Bonz for your service to your fellow man. I too am a long term and fairly heavy investor in ARTH. And being a past (knock on wood) frequent ortho patient I appreciate the potential of this device. I’ve had 16 surgeries on my left hip counting 3 revisions. Most of the complications stemmed from a n undetected, severe bone infection. During my last bout of surgeries I almost lost my leg and required 4 blood transfusions. Surely AC5 would have simplified matters some. All is good now. Gone are the days of triathlon racing. Simply walking relatively pain free is a pleasure.
Again, thank-you.
Cheers – Todd
Would love to hear @Clevelandโs take on the massive delay and Arthโs future, itโs too bad some people had to let accusations fly
You would think a simple sorry have no information to share at this time would be at the least ARTH could do. Has anyone contacted investors relations. Can we get the SEC involved somehow? Count me in on any revolt I’m all in.
$ARTH atlas long
I was wondering if someone could remind Archโs management to remind investors, both old and new, that their technology acts as a barrier from microbes too – no microbe gets through AC5 from one side to another.
*wink wink CORONA.
yours patiently ;),
Finn
@finventurer
Ah, Finn – ever the optimist.
Trying to keep up the good spirit, got nothing to lose anymore so thatโs all that i got left ๐
However cannot help wondering if the Dhillons have corrupted all that we once considered the technology of this millennium and everythingโs been waste of time.
Only thing i know is that we deserve better than this.
Anyways, keeping my fingers crossed for some good news before end of Q1.
yours, Finn
$ARTH Long
Ah, but the Corona Virus will provide TN and company the perfect excuse for not getting CE approval this quarter!. Nothing is getting done in Europe because of it, right?
Let’s see, only two more weeks in this quarter with no news today. Probably no news tomorrow cause it be St. Pats. That leaves two more Mon/Tues for TN to make good or kick the ball down the road once again.
$ARTH Long
.
You can get down on ARTH for a lot of things.
But this isn’t one of them.
That application was submitted what it seems like years ago.
There is nothing they can do – now or then – to speed up the process.
And with this latest worldwide crisis it may be delayed yet again.
The question is what is their plan – assuming the CE gets approved.
Maybe now – well – months from now.
We are looking at a possible global recession… Millions of layoffs here..
I still believe in the science. And the long-term of this….
But……Having said that…..
I think we need to band together and send messages to them…..
<<<<<<<<<<<<<<<>>>>>>>>>>>>>>
The whole World is hurting right now…โฆ.
We are not going to do another dilution just to pay your guy’s salary.
You need to bite the fuckin’ bullet in these trying times like everyone else.
<<<<<<<<<<<<<<<>>>>>>>>>>>>>>.
Who is on board..??
Couldn’t agree more. I’ve heard this story at least twice before – “We have the funds to get through (insert quarter)” and then dilution less than a month later. Sounds like from other comments, radio silence from IR when questioned about anything.
BRIEF-Arch Therapeutics Receives Marketing Clearance From The US FDA Related To The AC5 Topical Gel Supply Chain
7:54am ET, 03/23/2020 – Reuters
Well, finally some good news. Hopefully the stock price will respond accordingly. Still need that CE Mark though but it looks like its just a matter of time. And time is all we currently have……
Agree on it being good news. I wonder how the current pandemic and influx of new products to help with testing is affecting the timeliness of the notifying body’s decision. I admit I’m a bit ignorant of the how the process works, but would assume they probably have their hands full.
On a related note, I also hope a series of positive press releases will help drive the SP up, but am doubtful it will last. TN has mentioned that raising additional capital is a goal this year (obviously, as there isn’t enough cash on hand to last). My suspicion is probable dilution in the near future.
Here’s to hoping there’s a more substantial update this week when Norchi presents at Investor Summit:
https://ir.archtherapeutics.com/news/detail/535
$arth long, OW, and tired
Thanks for positing, Larry C!
$ARTH – Arch Therapeutics Receives Marketing Clearance from the US FDA Related to the AC5ยฎ Topical Gel Supply Chain
“As previously indicated, the Company was recently notified that the Notified Body review team has completed its review of Archโs technical documentation, provided the Company a draft of the CE certificate to review, and has recommended to its decision-making panel that CE Marking be granted.”
https://ir.archtherapeutics.com/press-releases/detail/536
ARTH long
If they had 3 mill cash on hand as of 12/31, and are burning through 1.7 mill per quarter… capital raise has to happen NOW, right? Without it they’d be out of business by early June. Am I missing something here?
$arth
Perhaps not at the time, but this morning ARTH got its CE Mark approval. Now, in the midst of this pandemic, we’ll get to see if it does us any good.
$ARTH Long.
https://ir.archtherapeutics.com/press-releases/detail/537/arch-therapeutics-receives-ce-mark-approval-for-ac5
FINALLY, now we need a good Q1 report and update from MR. NORCHI.
$ARTH Long
Well, only 2 weeks late from TN’s 1st Qtr. prediction, not bad for the times. However, about 2-3 years late from their first CE submission disaster.
Now the question is will the two or more distribution deals TN predicted for the 1st Qtr. happen soon or will the current world environment derail those deals?
https://ir.archtherapeutics.com/press-releases/detail/538/arch-therapeutics-to-provide-corporate-update-at-the
@drbonz
Seeing as how there is a presentation on $ARTH by Dr Norchi coming up this week, I’d like to send a message to the Arch Therapeutics Investor Relations Dept and quote your earlier missive to them, the one the IR people/person ignored before. Twice.
Is it OK with you if I do that?
Penny
Absolutely. Here it is again in case you couldn’t find it.
I have been a shareholder in ARTH for nearly 5 years now and obviously my interest is driven by this fact since weโd all like to make money. However, perhaps more importantly is the fact that I am also an orthopedic surgeon. I have read everything there is to know about AC5 and how it works and I believe it can truly be revolutionary in my field and in all surgical fields.
Late 2019 Dr. Norchi told us that he expected to have CE approval and several distribution deals completed in the first quarter of 2020. We are now in the middle of the first quarter of 2020 and I was wondering if there was anything you could pass along as far as a progress report or any information on the direction ARTH is going presently and going forward. Are any new studies being completed or planned? What is the current financial situation of the company?
As stated, I would love to see ARTH shares go up as it would benefit me financially but even more so, I would love to see AC5 in the hands of every surgeon in the country and in Europe. Using it could truly change the way we perform surgery and could benefit millions of patients worldwide.
I thank you for your time.
@drbonz
Done – thank you!
My message to Investor Relations:
“I belong to an investment group, the members of which, amongst us all, own a considerable number of $ARTH shares. Weโve held these shares for some 5 years now despite suffering periodic bouts of disillusionment and depression over the poor showing of the stock. We believe in the product, but we donโt understand what possible hurdles could there still be to having AC5 approved and released onto the market.
As one of our members put it a little earlier this year, and he is most excellently credentialed in his medical field to make educated comments about the use of AC5 (quoted):
. . . your words quoted . . .
We look forward to hearing Dr. Norchiโs presentation this week at the virtual conference and truly hope that it will not be yet another rendition of the same-old, same-old.
Sincerely,
(me)
Thank you for writing ARCH and expressing “OUR gummy” frustration!
Thank you for reaching out to Arch, the lack of input from Arch is (I will understate it as unfortunate.) Iit would be my best guess that they are having a difficult time moving the process from sample size to commercial quantities. I can see a scenario where production of AC5 up to this point has been in a lab producing maybe 250 or 500 mls at a time. Bringing this up to a commercial scale can be difficult.
I added today hoping they announce some sort of distribution deal next week and will get out before the massive dilution coming up.
Owning this stock has been nothing but torture.
$ARTH – Arch Therapeutics, Inc. to Present at the Virtual Investor Fireside Chat Series
This makes the 12th and the 15th, That TN will be busy with investors. Is there some significance there?
https://ir.archtherapeutics.com/press-releases/detail/540
ARTH long
Torture is an understatement.
Looks like the ‘goo’ has an order page now.
https://www.archtherapeutics.com/products/ordering-information
I listened to the presentation from the other day.
They were excited they shipped product to KOLโs. Um, werenโt they supposed to do that end of last summer?
Theyโre distributing themselves. (Shipping free samples probably.)
Perspective partners still excited! (The ones that havenโt partnered yet or put up 1 cent of money.)
To recap, no sales of AC5 18 months after approval.
Not one partner deal.
No distribution in place.
Not one internal trial started.
About to dilute hundreds of millions of shares.
Great job Terry and team!!!!!
$ARTH Long OW
I just received proxy notices to vote for granting authority to the company to increase capitalization up to 800,000,000 shares. I am voting against. Not that it will make any difference, they have the shares to vote themselves more shares for more fat salaries for years to come. But perhaps if we all voted against, a statement, futile that it will be, can be made.
I concur. The least we can do is show other shareholders how many shares are not happy with the company’s performance.
Count me in.
Just voted against.
Just voted against. Twice.
Thanks for the updates, and spot-on commentary!
Just did my proxyvote thing to vote AGAINST for as many of the accounts as I have control over, and have emailed the rest to suggest what a better action might be for them to take as shareholders.